Stem Cell Therapy Archives - Medical Conferences

Potential benefit of autologous cell therapy in patients with ischaemic HFrEF?

Presented By

Prof. Amish Raval, University of Wisconsin – Madison, WI, USA

Trial

CardiAMP-HF

Conference

ACC 2025

Type

Peer-reviewed article

22 May 2025 15:09

Could stem cell transplantation be a fruitful solution for refractory CD?

Presented By

Dr Louis Cohen, Icahn School of Medicine at Mount Sinai, NY, USA

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 11:24

Can we omit auto-SCT in patients with mantle cell lymphoma with undetectable MRD post-induction?

Presented By

Dr Timothy Fenske, Medical College of Wisconsin, WI, USA

Trial

Phase 3, EA4151

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:23

Allo-SCT improves lives of children with sickle cell anaemia and abnormal cerebral artery velocities

Presented By

Dr Françoise Bernaudin, Centre Hospitalier Intercommunal Creteil, France

Trial

DREPAGREFFE-2

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:33

Encouraging real-world results of AHSCT to treat aggressive MS

Presented By

Prof. Paolo Muraro, London Bridge Hospital, UK

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:35

Updates from the EBMT Lymphoma Working Group: outcomes after allo- and auto-SCT for T-cell lymphoma subtypes

Presented By

Dr Evgenii Shumilov, University of Münster, Germany

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:27

RUBY: Promising data for first AsCas12a gene-editing therapy in sickle cell disease

Presented By

Dr Rabi Hanna, Cleveland Clinic, OH, USA

Trial

Phase 1/2, RUBY

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:25

MRD status rather than FLT3-ITD co-mutation is linked to the benefit of CR1-allo in NPM1-mutated AML

Presented By

Dr Jad Othman, Royal North Shore Hospital, Australia

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:04

Promising results for quizartinib, venetoclax, and decitabine in FLT3-ITD mutated AML

Presented By

Dr Musa Yilmaz, MD Anderson Cancer Center, TX, USA

Trial

Phase 1/2

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:04

Is allogeneic stem cell transplantation a solid option in R/R LBCL or R/R T-cell lymphoma?

Presented By

Prof. Bertram Glass, Helios Klinikum Berlin-Buch, Germany

Trial

Phase 2, ASTRAL

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:00

Can ibrutinib ameliorate outcomes in R/R ABC-DLBCL undergoing autoSCT?

Presented By

Dr Charalambos Andreadis, University of California San Francisco, USA

Trial

Phase 3, A051301/BMT-CTN 1201

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:59

IsKia: Novel treatment regimen for MM delivers high MRD-negativity rates

Presented By

Prof. Francesca Gay, University of Torino, Italy

Trial

Phase 3, IsKia

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:57

Novel standard-of-care in newly diagnosed MM

Presented By

Prof. Pieter Sonneveld, Erasmus MC, the Netherlands

Trial

Phase 3, Perseus

Conference

ASH 2023

Type

Peer-reviewed article

6 February 2024 16:34

QuANTUM-First: Updated results on quizartinib in AML with FLT3-ITD

Presented By

Dr Richard Schlenk, University of Heidelberg, Germany

Trial

Phase 3, QuANTUM-First

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:54

Stem cell therapy fails primary endpoint but improves walking in more advanced progressive MS

Trial

Phase 2

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:30

Can molecular data improve prognostication in MDS patients undergoing HSCT?

Presented By

Dr Carmelo Gurnari, Cleveland Clinic, OH, USA & Tor Vergata University, Italy

Conference

EMBT 2023

Type

Peer-reviewed article

15 June 2023 17:27

Novel drugs and strategies around ASCT for Hodgkin lymphoma

Presented By

Dr Anna Sureda, Catalan Institute of Oncology, Spain

Conference

EBMT 2023

Type

Peer-reviewed article

15 June 2023 17:15

New options to treat steroid-refractory chronic GvHD

Presented By

Prof. Mohamad Mohty, Sorbonne University, France

Conference

EBMT 2023

Type

Peer-reviewed article

15 June 2023 16:59

ASCT or CAR T cell as first-line therapy for MM?

Presented By

Prof. Salomon Manier, Lille University Hospital, France

Trial

Phase 3, CARTITUDE-6

Conference

EBMT 2023

Type

Peer-reviewed article

14 June 2023 20:23

DETERMINATION: Does one size fit all in multiple myeloma?

Presented By

Dr Hani Hassoun, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, DETERMINATION

Conference

EBMT 2023

Type

Peer-reviewed article

14 June 2023 20:14

Quizartinib plus chemotherapy improves OS in patients with AML undergoing ASCT

Presented By

Prof. Radovan Vrhovac, University Hospital Centre Zagreb, Croatia

Trial

Phase 3, QuANTUM-First

Conference

EMBT 2023

Type

Peer-reviewed article

14 June 2023 20:07

Blinatumomab may improve outcomes in patients with B-cell ALL undergoing ASCT

Presented By

Dr Ayman Sayyed, University of Toronto, Canada

Conference

EBMT 2023

Type

Peer-reviewed article

14 June 2023 20:02

Is ASCT a reasonable option in patients with invasive aspergillosis?

Presented By

Prof. Olaf Penack, Charité University Hospital of Berlin, Germany

Conference

EBMT 2023

Type

Peer-reviewed article

14 June 2023 19:55

Tacrolimus versus cyclosporin A in AML

Presented By

Dr Gesine Bug, Goethe University Frankfurt, Germany

Conference

EBMT 2023

Type

Peer-reviewed article

14 June 2023 19:48

Neutrodiet: non-restricted diet is the preferred option after SCT

Presented By

Prof. Federico Stella, Università degli Studi di Milano, Italy

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 13:11

Ibrutinib added to ASCT improves clinical outcomes in mantle cell lymphoma

Presented By

Prof. Martin Dreyling, University Hospital Munich, Germany

Trial

Phase 3, Triangle

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:39

High-dose chemotherapy plus ASCT superior to standard immuno-chemotherapy in primary CNS lymphoma

Presented By

Prof. Gerald Illerhaus, Klinikum Stuttgart, Germany

Trial

Phase 3, MATRix/IELSG43

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:37

Should we use intensive chemotherapy prior to allo-HCT in relapsed/refractory AML?

Presented By

Prof. Matthias Stelljes, University of Muenster, Germany

Trial

Phase 3, EATL3-ASAP

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:13

Stem cell transplantation not superior to natalizumab in progressive MS

Presented By

Prof. Tomas Kalincik, Royal Melbourne Hospital, Australia

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 09:37

Autologous haematopoietic stem cell transplantation versus DMTs

Presented By

Prof. Tomas Kalincik, University of Melbourne, Australia

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 08:52

ECTRIMS 2022 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ECTRIMS 2022

15 November 2022 00:08

Autologous stem cell transplantation plus RVd improves PFS in multiple myeloma

Presented By

Prof. Paul Richardson, Harvard Medical School, MA, USA

Trial

Phase 3, DETERMINATION

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:33

Investigational therapies superior to standard-of-care in double-exposed CLL

Presented By

Dr Meghan Thompson, Memorial Sloan Cancer Center, NY, USA

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:36

Novel anti-CD19 plus lenalidomide prolonged survival in R/R DLBCL

Expert

Dr Grzegorz Nowakowski, Mayo Clinic, Rochester, USA

Trial

Cohort study, RE-MIND2

Conference

ASH 2021

Type

News article

4 February 2022 11:08

Liso-cel superior to standard-of-care as second-line therapy in large B-cell lymphoma

Expert

Dr Manali Kamdar, University of Colorado Cancer Center, Denver, USA

Trial

Phase 3, TRANSFORM

Conference

ASH 2021

Type

News article

4 February 2022 10:28

Axi-cel improved event-free survival in relapsed/refractory large B-cell lymphoma

Expert

Dr Frederick Locke, Moffitt Cancer Cancer, Tampa, Florida, USA

Trial

Phase 3, ZUMA-7

Conference

ASH 2021

Type

News article

4 February 2022 10:10

Comparable outcomes with second-line tisa-cel versus standard-of-care for relapsed/refractory aggressive NHL

Expert

Dr Michael R. Bishop, David and Etta Jonas Center for Cellular Therapy, University of Chicago, USA

Trial

Phase 3, BELINDA

Conference

ASH 2021

Type

News article

4 February 2022 10:03

Personalising treatment for sickle cell disease

Presented By

Dr Erfan Nur, Amsterdam University Medical Center, the Netherlands

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 15:38

Reduced-intensity conditioning ASCT is effective in older patients with AML

Presented By

Prof. Nigel Russell, Guy's Hospital, UK

Trial

AML16; AML18

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 13:55

Immuno-oncology agents are effective in treating classic Hodgkin’s lymphoma

Presented By

Dr Marc André, Centre Hospitalier Universitaire UCL Namur, Belgium

Trial

CheckMate 205; KEYNOTE-087

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 12:26

MATRix with ASCT: best long-term survival for primary CNS lymphoma

Presented By

Dr Gerald Illerhaus, Klinikum der Landeshauptstadt Stuttgart, Germany

Trial

Phase 2, IELSG32

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 12:05

Pembrolizumab improves PFS for relapsed/refractory Hodgkin lymphoma

Presented By

Prof. Pier Luigi Zinzani, University of Bologna, Italy

Trial

Phase 3, KEYNOTE-204

Conference

EHA 2020

Type

Peer-reviewed article

9 September 2020 12:38

HOVON-96: Better outcomes with cyclophosphamide after transplantation

Presented By

Dr Annoek Broers, Erasmus MC Cancer Institute, the Netherlands

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 23:53

Likely new standard of care: Blinatumomab for children with relapsed B-ALL

Presented By

Prof. Patrick A. Brown, Johns Hopkins Kimmel Cancer Center, Baltimore, USA

Trial

Phase 3, AALL1331

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 23:15

BCL11A as a novel target in gene therapy for sickle cell disease

Presented By

Dr David Williams, Boston Children’s Hospital, USA

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 20:45

MRD assessment to guide pre-emptive treatment decisions

Presented By

Prof. Uwe Platzbecker, University Hospital Carl Gustav Carus, Germany

Trial

Phase 2, RELAZA2

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 16:04

Abatacept prevents graft-versus-host disease in sickle cell patients after alloSCT

Presented By

Dr Niketa Shah, Yale University, USA

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 15:20

Experimental model for limitations of haematopoietic stem cells propagation

Presented By

Dr Jennifer Myers SanMiguel, The Jackson Laboratory, USA

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 14:47

Updated results ECOG-ACRIN E2906: decitabine maintenance after alloSCT

Presented By

Dr Xiaowen Tang; Dr James Foran

Trial

Phase 2, ECOG-ACRIN E2906

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 13:16

Induction therapy over treatment escalation

Presented By

Prof. Alasdair Coles, Cambridge University Hospitals, United Kingdom

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 23:38

Autologous haematopoietic stem cell transplantation

Presented By

Dr Alice Mariottini, Careggi University Hospital, Italy

Trial

Phase 3, MIST

Conference

EAN 2019

Type

Peer-reviewed article

27 August 2019 14:38

Haematopoietic stem cell transplantation improves stroke risk in children with sickle cell anaemia

Presented By

Dr Francoise Bernaudin, Intercommunal Hospital Center de Créteil, France

Trial

DREPAGREFFE

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 21:52

Haematopoietic stem cells can sense tissue damage in the gut

Presented By

Dr Hitoshi Takizawa, Kumamoto University, Japan

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 20:19

Mesenchymal stem cells in a proof-of-concept study

Conference

AAN 2019

Type

Peer-reviewed article

30 July 2019 21:31

Stem cell therapy in acute respiratory distress syndrome improves 28-day mortality

Presented By

Dr Geoff Bellingan, University College London, United Kingdom

Trial

MUST-ARDS

Conference

ATS 2019

Type

Peer-reviewed article

23 July 2019 23:28